文献速递抗栓抗凝管理药物不良反应与药物警戒

澳大利亚对华法林短缺的全国应对:评估监管替代与通知短缺及其对抗血栓药物配发、病理监测和不良事件趋势的影响

A National Response to Warfarin Shortages: Evaluating Regulatory Substitution and Notified Shortages and Their Effects on Antithrombotic Dispensings, Pathology Monitoring and Adverse Event Trends in Australia.
PubMed 文献 · Drug Saf · 2025-11-04

本研究评估2023年澳大利亚华法林短缺期间,治疗用品管理局通过严重短缺替代文书允许药师以低规格华法林片替代5毫克片的影响。结果显示华法林配发在SSSI实施后短期增加但未持续,DOAC配发在2023年3月后下降,INR检测短暂增加,出血相关不良事件略有上升。结论认为基于规格的替代维持了华法林供应,对DOAC配发影响有限。

要点

  • SSSI实施后华法林配发短期增加8625张处方,但未持续。
  • 5毫克华法林配发下降,1毫克和2毫克上升,3毫克稳定。
  • DOAC配发在2023年3月后每月下降3056张处方。

核心结论

  • 通过SSSI基于规格的替代维持了2023年短缺期间华法林供应,对DOAC配发影响有限。

研究设计与样本

  • 基于澳大利亚PBS配发数据、Services Australia的INR病理数据和TGA不良事件数据库的间断时间序列分析,覆盖2020年1月至2024年8月月度全国数据。

主要发现

  • 2023年3月前华法林配发每月下降1094张处方(p<0.0001)。
  • SSSI实施后2023年3月华法林配发短期增加8625张处方(p=0.0017),但未持续。
  • 华法林1毫克和2毫克配发上升,5毫克下降后补偿性增加,3毫克稳定。
  • 2023年3月前DOAC配发每月增加3771张处方(p<0.0001),之后每月下降3056张处方(p<0.0001),利伐沙班和达比加群下降最明显,阿哌沙班下降不显著。
  • 短缺和SSSI期间INR检测短暂增加,出血相关不良事件略有上升。

临床怎么用

  • 在华法林5毫克片短缺时,可依据SSSI允许药师以低规格片替代,维持抗凝治疗连续性。
  • 短缺期间应加强INR监测,关注出血相关不良事件信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medicine shortages are an increasing threat to medicine safety and access. In Australia, a 7-month shortage of Coumadin 5-mg tablets (Dec 2022-Jul 2023) prompted Therapeutic Goods Administration (TGA) intervention via the Serious Scarcity Substitution Instrument (SSSI), allowing pharmacists to substitute 5-mg warfarin tablets with lower-strength tablets. Understanding the impact of this shortage on anticoagulant use and safety is essential for informing future regulatory responses. AIMS: The aim of this study was to assess the impact of the 2023 warfarin shortage in Australia on dispensing of warfarin and direct oral anticoagulants (DOACs), International Normalised Ratio (INR) testing, and adverse event reporting. METHODS: Monthly national dispensing data (January 2020-August 2024) were obtained from Pharmaceutical Benefits Scheme (PBS) Date of Supply data. INR pathology data were sourced from Services Australia. The TGA Medicines Shortages Database identified relevant shortage periods. Warfarin-related adverse events were extracted from the TGA Database of Adverse Event Notifications. Interrupted time series assessed changes in dispensing and INR testing trends over time. RESULTS: Warfarin dispensing declined by 1094 prescriptions per month prior to March 2023 (p < 0.0001). A short-term increase occurred in March 2023 (+ 8625 prescriptions; p = 0.0017) following implementation of the SSSI, although this was not sustained. At the warfarin strength level, dispensing rose for warfarin 1 mg and 2 mg but fell for 5 mg, with subsequent compensatory increases; 3 mg remained stable. DOAC dispensing increased steadily before March 2023 (+ 3771 prescriptions per month; p < 0.0001) but declined thereafter (- 3056 per month; p < 0.0001), most notably for rivaroxaban and dabigatran, while apixaban decreased non-significantly. INR testing briefly increased during the shortage and SSSI. A modest rise in haemorrhage-related adverse events was observed. CONCLUSION: Warfarin supply was maintained during the 2023 shortage through strength-based substitution under the SSSI, with limited impact on DOAC dispensing.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Azroun R, Ellett LK, Pratt N, et al. A National Response to Warfarin Shortages: Evaluating Regulatory Substitution and Notified Shortages and Their Effects on Antithrombotic Dispensings, Pathology Monitoring and Adverse Event Trends in Australia. Drug Saf. 2025. PMID: 41186801. doi:10.1007/s40264-025-01633-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。